RxDoctor Payments Data

Francis Vazquez Roura, MD

Nephrology · Ponce, PRNPI 1194807461

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (58.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Johnson & Johnson at 44.5% of the total. Reporting peaked in 2019 at $2,635 and has fallen 72.2% since, to $732 in 2025.

$5,617in general payments, 2019–2025

Across 75 payments — averaging $74.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Bayer Puerto Rico Inc.$827
  • Bayer$682
  • AstraZeneca$624
  • Fresenius USA Marketing, Inc.$292
  • GSK$235
  • plus $460 from 6 others

What the payments were for

  • Consulting fees$2,04036%
  • Travel & lodging$2104%
  • Food & beverage$3,26758%
  • Education$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,617 in reported general payments places this provider in the 85th percentile of 161 nephrology providers in Puerto Rico.

See all nephrology providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$38,677
Medicare patients
48
Services billed
260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol970$645,787
JardianceEmpagliflozin650$458,824
Sevelamer Carbonate536$61,331
KerendiaFinerenone57$49,228
Lanthanum Carbonate107$46,455
EliquisApixaban12$7,155
Sodium Polystyrene Sulfonate63$7,034
Calcium Acetate32$2,822
SynthroidLevothyroxine Sodium37$2,321
Nifedipine ErNifedipine91$2,316
HumalogInsulin Lispro24$2,169
LantusInsulin Glargine,hum.Rec.Anlog28$2,137
Irbesartan82$1,698
Minoxidil41$1,614
Losartan Potassium163$1,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$624$645,787970 claims
Boehringer IngelheimJardiance$117$458,824650 claims
BayerKerendia$682$49,22857 claims
ANI Pharmaceuticals, Inc.Valsartan$84$50813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 161 nephrology providers in Puerto Rico.

Other nephrology in Ponce

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →